Prante Olaf, Einsiedel Jürgen, Haubner Roland, Gmeiner Peter, Wester Hans-Jürgen, Kuwert Torsten, Maschauer Simone
Laboratory of Molecular Imaging, Clinic of Nuclear Medicine, Friedrich-Alexander University, 91054 Erlangen, Germany.
Bioconjug Chem. 2007 Jan-Feb;18(1):254-62. doi: 10.1021/bc060340v.
3,4,5-Tri-O-acetyl-2-[18F]fluoro-2-deoxy-d-glucopyranosyl 1-phenylthiosulfonate (Ac3-[18F]FGlc-PTS) was developed as a thiol-reactive labeling reagent for the site-specific 18F-glycosylation of peptides. Taking advantage of highly accessible 1,3,4,6-tetra-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranose, a three-step radiochemical pathway was investigated and optimized, providing Ac3-[18F]FGlc-PTS in a radiochemical yield of about 33% in 90 min (decay-corrected and based on starting [18F]fluoride). Ac3-[18F]FGlc-PTS was reacted with the model pentapeptide CAKAY, confirming chemoselectivity and excellent conjugation yields of >90% under mild reaction conditions. The optimized method was adopted to the 18F-glycosylation of the alphavbeta3-affine peptide c(RGDfC), achieving high conjugation yields (95%, decay-corrected). The alphavbeta3 binding affinity of the glycosylated c(RGDfC) remained uninfluenced as determined by competition binding studies versus 125I-echistatin using both isolated alphavbeta3 and human umbilical vein endothelial cells (Ki = 68 +/- 10 nM (alphavbeta3) versus Ki = 77 +/- 4 nM (HUVEC)). The whole radiosynthetic procedure, including the preparation of the 18F-glycosylating reagent Ac3-[18F]FGlc-PTS, peptide ligation, and final HPLC purification, provided a decay-uncorrected radiochemical yield of 13% after a total synthesis time of 130 min. Ac3-[18F]FGlc-PTS represents a novel 18F-labeling reagent for the mild chemoselective 18F-glycosylation of peptides indicating its potential for the design and development of 18F-labeled bioactive S-glycopeptides suitable to study their pharmacokinetics in vivo by positron emission tomography (PET).
3,4,5-三-O-乙酰基-2-[¹⁸F]氟-2-脱氧-D-吡喃葡萄糖基苯硫代磺酸酯(Ac3-[¹⁸F]FGlc-PTS)被开发为一种用于肽的位点特异性¹⁸F-糖基化的硫醇反应性标记试剂。利用易于获得的1,3,4,6-四-O-乙酰基-2-脱氧-2-[¹⁸F]氟葡萄糖,研究并优化了一条三步放射化学途径,在90分钟内以约33%的放射化学产率(衰变校正且基于起始[¹⁸F]氟化物)提供了Ac3-[¹⁸F]FGlc-PTS。Ac3-[¹⁸F]FGlc-PTS与模型五肽CAKAY反应,在温和反应条件下证实了化学选择性和大于90%的优异偶联产率。将优化后的方法应用于αvβ3亲和肽c(RGDfC)的¹⁸F-糖基化,获得了高偶联产率(95%,衰变校正)。通过使用分离的αvβ3和人脐静脉内皮细胞进行与¹²⁵I-echistatin的竞争结合研究确定,糖基化的c(RGDfC)的αvβ3结合亲和力不受影响(αvβ3的Ki = 68 ± 10 nM,而人脐静脉内皮细胞的Ki = 77 ± 4 nM)。整个放射合成过程,包括¹⁸F-糖基化试剂Ac3-[¹⁸F]FGlc-PTS的制备、肽连接和最终的HPLC纯化,在130分钟的总合成时间后提供了13%的未衰变校正放射化学产率。Ac3-[¹⁸F]FGlc-PTS代表了一种用于肽的温和化学选择性¹⁸F-糖基化的新型¹⁸F标记试剂,表明其在设计和开发适合通过正电子发射断层扫描(PET)在体内研究其药代动力学的¹⁸F标记生物活性S-糖肽方面的潜力。